The Effect of 0.01% Atropine Eye Drops on the Ocular Surface in Children for the Control of Myopia—The Primary Results from a Six-Month Prospective Study
Received 8 June 2020
Accepted for publication 27 July 2020
Published 10 August 2020 Volume 2020:16 Pages 735—740
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Jingyi Cheng,1– 3,* Yujing Yang,1– 3,* Xiehe Kong,4 Li Zeng,1– 3 Zhi Chen,1– 3 Jianjiang Xu,1– 3 Chaoran Zhang1– 3
1Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College of Fudan University, Shanghai, People’s Republic of China; 2Key Laboratory of Myopia, Ministry of Health (Fudan University), Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University), Shanghai, People’s Republic of China; 4Shanghai Research Institute of Acupuncture and Meridian, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chaoran Zhang
Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College of Fudan University, 83 Fenyang Road, Shanghai 200031, People’s Republic of China
Tel/ Fax +86 2164377134
Purpose: To evaluate the effect of 0.01% atropine eye drops on the ocular surface in children for the control of myopia.
Methods: A total of 72 participants were recruited for this prospective study. Prior to and after 1, 3, and 6 months of 0.01% atropine administration, an ocular surface disease index (OSDI) questionnaire was obtained, Keratograph 5M was used for the measurement of the tear meniscus height (TMH), noninvasive keratographic tear film break-up time (NK-BUT, the first keratographic break-up time, [NK-BUTfirst] and the average keratographic break-up time, [NK-BUTave]), bulbar redness (BR), meiboscore (MS), and anterior segment optical coherence tomography (AS-OCT) was used to calculate the inferior tear meniscus area (TMA).
Results: After using the 0.01% atropine eye drops for 1 month, 9 subjects complained of discomfort immediately after administration, but this quickly subsided, and 1 subject was temporarily dazzled. All the ocular surface symptoms were mild and occurred rarely. After 3 months, these complaints no longer occurred. Compared with the baseline values, the OSDI scores (0.08 ± 0.28), values of TMH (0.23 ± 0.04 mm), TMA (0.0420 ± 0.0444 mm2), NK-BUTfirst (9.39 ± 5.25 s), NK-BUTave (10.49 ± 4.94 s), BR (0.63 ± 0.37), and MS (0.89 ± 0.70) did not change significantly after 6 months of 0.01% atropine eye drop administration (P > 0.05).
Conclusion: In this 6-month prospective study, no side effects were observed on the ocular surface after using 0.01% atropine in children.
Keywords: 0.01% atropine eye drops, ocular surface, children, myopia control
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]